IPS-Integrated Project Services’ Post

We're pleased to announce that we are joining the 3Rs Collaborative Microphysiological Systems Initiative. Microphysiological systems (MPS) look to overcome some of the limitations seen in existing in vivo and basic in vitro systems, aiming to increase translation, efficiency, efficacy, and safety of models for drug development. MPS are diverse in nature and include tissue models such as spheroids, organoids, and organs-on-chips. The 3RsC-MPS Initiative comprises 82 representatives from 39 institutions, including 28 providers of commercially available MPS (that are already translated into industry use) as well as several end-users. Its principal goal is to increase the adoption of MPS technologies through stakeholder engagement. Read more here: https://hubs.la/Q02BjL-y0 #MPS #3rs #MicrophysiologicalSystems #StemCells #iPSCs

Proud to support the 3Rs Collaborative Microphysiological Systems Initiative. Microphysiological systems (MPS) look to overcome some of the limitations seen in existing in vivo and basic in vitro systems, aiming to increase translation, efficiency, efficacy, and safety of models for drug development. MPS are diverse in nature and include tissue models such as spheroids, organoids, and organs-on-chips. The 3RsC-MPS Initiative comprises 82 representatives from 39 institutions, including 28 providers of commercially available MPS (that are already translated into industry use) as well as several end-users. Its principal goal is to increase the adoption of MPS technologies through stakeholder engagement. Read more here: https://hubs.la/Q02BjL-y0

First day of #TIDES2024: insightful talks this morning on the progress from Beam Therapeutics and Prime Medicine, Inc. in base editing and prime editing, respectively.

𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝗶𝘁'𝘀 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝘁𝗼 𝗰𝗼𝗺𝗯𝗶𝗻𝗲 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗠𝗖𝗧 𝗣𝗿𝗲𝘀𝗲𝘁𝘀? By combining PRP or Cells presets with the Exosomes preset, we can achieve even more potent therapeutic outcomes. Here’s how it works: 𝟭. 𝗦𝗽𝗹𝗶𝘁𝘁𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹: The patient’s material is divided into two equal halves. 𝟮. 𝗙𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳: Used for PRP or Cells presets to obtain either MCT Plasma or MCT Cells. 𝟯. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗵𝗮𝗹𝗳: Used to run the Exosomes preset, generating MCT Exosomes. This approach allows patients to benefit from both MCT Plasma or MCT Cells and MCT Exosomes, providing an enhanced treatment experience. #MCT #PRP #Exosomes #Cells #MCTCombinedTreatment

We're pleased to announce that we are joining the 3Rs Collaborative Microphysiological Systems Initiative. Microphysiological systems (MPS) look to overcome some of the limitations seen in existing in vivo and basic in vitro systems, aiming to increase translation, efficiency, efficacy, and safety of models for drug development. MPS are diverse in nature and include tissue models such as spheroids, organoids, and organs-on-chips. The 3RsC-MPS Initiative comprises 82 representatives from 39 institutions, including 28 providers of commercially available MPS (that are already translated into industry use) as well as several end-users. Its principal goal is to increase the adoption of MPS technologies through stakeholder engagement. Read more here: https://hubs.la/Q02BjgJ70 #MPS #3rs #MicrophysiologicalSystems #StemCells #iPSCs

☑️ Boston Scientific secures a CE mark for its Deep Brain Stimulation software, aimed at aiding clinicians in programming devices for early-stage Parkinson's disease. ☑️ Medtronic reports positive results from a study on its MiniMed 780G system, showing reduced diabetes burden. ☑️ Alcon obtains FDA 510(k) approval for its Unity VCS and CS systems, which are expected to enhance workflow efficiencies. ☑️ Insulet Corporation plans label expansion for its Omnipod system in type 2 diabetes following positive trial data showing glycaemic improvements. ☑️ Sequel Med Tech received FDA clearance in March for its unique twiist automated insulin delivery system, introducing a novel option in the diabetes management market. #InsightswithSmarteeva #Medtech #complaintmanagement #Pharma #Smarteeva #biotech #medtechtrends #medtechindustry #medicaltechnology #technology #health #medicaldevicediagnostics #ai #mdr #recalls #complaints #mir #fda #cvr

#Article now available! #iPSC-ing into the future of #celltherapy: expansion in a hollow-fiber #bioreactor The development of iPSC-derived therapies requires high-quality iPSC banks generated via standardized workflows to minimize starting material bank-to-bank variability. In this article, the transition from manual to automated #iPSCexpansion is described, followed by an exploration of how to effectively expand high-quality iPSCs in a functionally closed, automated, and scalable system using hollow-fiber perfusion technology. Read at your convenience below:

Promising news from EHA 2024! CARsgen Therapeutics' CT071 is showing encouraging results in treating relapsed/refractory multiple myeloma (RRMM). CT071, a CAR T-cell therapy targeting GPRC5D, is produced using CARsgen's CARcelerateTM platform, which accelerates manufacturing to under 2 days, resulting in more effective CAR T cells. Preliminary data from the first-in-human trial (#NCT05838131) showed a 90% overall response rate (ORR), with 100% MRD negativity among evaluable patients. Despite some Grade 3 or higher hematologic toxicities, all treatment-related adverse events were resolved. CT071's expedited production and promising efficacy offer hope for RRMM patients, especially those previously treated with BCMA-targeting therapies. With the ongoing Phase I trial, CARsgen Therapeutics is poised to make a significant impact in the multiple myeloma treatment landscape. Get detailed analysis of the abstract here @ https://lnkd.in/gHZbPH2w Stay tuned for more updates on this innovative therapy! #CARsgenTherapeutics #CT071 #MultipleMyeloma #CARcelerate #EHA2024 #ClinicalTrials #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #multiplemyeloma #pharmacautical #hematology #eha24 #cart #celltherapy

Promising news from European Hematology Association (EHA) 2024! CARsgen Therapeutics' CT071 is showing encouraging results in treating relapsed/refractory multiple myeloma (RRMM). CT071, a CAR T-cell therapy targeting GPRC5D, is produced using CARsgen's CARcelerateTM platform, which accelerates manufacturing to under 2 days, resulting in more effective CAR T cells. Preliminary data from the first-in-human trial (#NCT05838131) showed a 90% overall response rate (ORR), with 100% MRD negativity among evaluable patients. Despite some Grade 3 or higher hematologic toxicities, all treatment-related adverse events were resolved. CT071's expedited production and promising efficacy offer hope for RRMM patients, especially those previously treated with BCMA-targeting therapies. With the ongoing Phase I trial, CARsgen Therapeutics is poised to make a significant impact in the multiple myeloma treatment landscape. Get detailed analysis of the abstract here @ https://lnkd.in/eVb7TqPa Stay tuned for more updates on this innovative therapy! #CARsgenTherapeutics #CT071 #MultipleMyeloma #CARcelerate #EHA2024 #ClinicalTrials #healthcare #business #clinicalstudies #clinicaltrials #results #phases #top #abstracts #multiplemyeloma #pharmacautical #hematology #eha24 #cart #celltherapy

🔹 IN CONVERSATION with Dr. Simon Graindorge 🔹 2024 is shaping up to be a pivotal year for OncoRes Medical. As we advance our innovative technology, generating robust evidence that supports regulatory approval and demonstrates our positive impact on patients is a top priority. In the first installment of our In Conversation series, OncoRes’ Chief Operating Officer, Dr. Simon Graindorge, provides insights into our current clinical trials, timelines for key milestones, and our commitment to fostering medical device innovation in Australia. Take a look 👉 https://lnkd.in/gZ45F4v7 #OncoRes #medtech #innovation #breastcancer #breastconservation #breastconservationsurgery #lumpectomy #patientsfirst #patientoutcomes